Skip to main content
Clinical Trials/NCT06118983
NCT06118983
Recruiting
Not Applicable

Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF): A Type 1 Hybrid Effectiveness- Implementation Trial

Weill Medical College of Cornell University2 sites in 1 country1,094 target enrollmentJuly 1, 2026
ConditionsHeart Failure

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Weill Medical College of Cornell University
Enrollment
1094
Locations
2
Primary Endpoint
All-cause 30-day hospital readmission
Status
Recruiting
Last Updated
8 months ago

Overview

Brief Summary

This study is trying to improve the hospital-to-home transition for people with heart failure who receive home care services. The study will test an intervention called I-TRANSFER-HF, which differs from usual care by combining early home health nurse visits and outpatient medical appointments.

The study is interested in two questions:

  1. Is I-TRANSFER-HF better than usual care at preventing heart failure patients from returning to the hospital within 30 days?
  2. Are there parts of I-TRANSFER-HF that are easy or hard to implement in the real world?

The researchers will answer these questions by testing the intervention among pairs of hospitals and home health agencies across the country. During the study, the hospital-agency pairs will be asked to implement I-TRANSFER-HF. The researchers will then compare the results from before and after I-TRANSFER-HF was adopted. They will also interview people from these hospitals and agencies to see how I-TRANSFER-HF is being implemented under real-world conditions.

Detailed Description

The investigators' will test two hypotheses: Hypothesis 1 (H1): Compared to usual care, adults with heart failure who receive the I-TRANSFER-HF intervention will have fewer 30-day readmissions, ED visits, and greater days at home. The four hospital-agency pairs will all begin the study with a baseline period of no intervention and then randomly selected to start the intervention phase at different points in time. Medicare claims data from each hospital-agency pair will be used to determine outcomes, and these data will be supplemented with national claims data for external controls not in the study to test the effectiveness of the I-TRANSFER-HF intervention. Hypothesis 2 (H2): Compared to usual care, heart failure patients who receive I-TRANSFER-HF will have a higher proportion of timely first week HHC nursing visits (within 2 days of hospital discharge, plus 2 more) and outpatient visits (within 7-days of discharge). Given the rise of telemedicine, the study will test the association between the type of outpatient visit (in-person vs. virtual), its timing, and its association with outcomes. H2 requires conducting qualitative interviews with key stakeholders across the 4 hospital-agency pairs to identify barriers and facilitators that influence I-TRANSFER-HF's implementation. The study will assess the intervention's acceptability, feasibility, fidelity, and adaptation with interviews and Medicare claims data using a multi-methods approach and guided by the updated Consolidated Framework for Implementation Research (CFIR 2.0).

Registry
clinicaltrials.gov
Start Date
July 1, 2026
End Date
July 1, 2028
Last Updated
8 months ago
Study Type
Interventional
Study Design
Sequential
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adults hospitalized for HF who transition from participating hospitals to their partner HHC agency during the study period.

Exclusion Criteria

  • Patients hospitalized for HF and discharged: home without HHC, or to an inpatient rehabilitation facility, skilled nursing facility, or hospice; patients with end stage renal disease on dialysis and those with left ventricular devices.
  • Aim 2, Inclusion Criteria:
  • Healthcare professional involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.
  • Aim 2, Exclusion Criteria:
  • Healthcare professional not involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.

Outcomes

Primary Outcomes

All-cause 30-day hospital readmission

Time Frame: 30 days following post-Index HF Hospitalization

All-cause 30-day hospital readmission among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims

Number of Eligible patients

Time Frame: 12 months

Number of heart failure patients eligible to receive I-TRANSFER-HF as assessed by Medicare claims data

Number of Eligible Patients Who Received Protocol Components

Time Frame: 12 months

Number of heart failure patients who received both components of I-TRANSFER-HF (front-loaded home health nurse visits and early outpatient medical follow-up), one, or none as assessed by Medicare claims data

Modality of outpatient follow-up

Time Frame: 12 months

The modality of outpatient follow-up received (in-person vs. virtual visit) as assessed by Medicare claims data

Timeliness of Post-Hospital Discharge Home Health Nursing Evaluation

Time Frame: 12 months

The timeliness of first-week nursing visits within 2 days of hospital discharge as assessed by Medicare claims data

Timeliness of Post-Hospital Outpatient Follow-Up

Time Frame: 12 months

The timeliness of outpatient visits within 7 days of hospital discharge as assessed by Medicare claims data

Feasibility of implementing I-TRANSFER-HF (Qualitative Interviews)

Time Frame: 30 days after intervention (year of intervention)

Feasibility will be assessed through qualitative interviews with site stakeholders

Feasibility of implementing I-TRANSFER-HF (Surveys)

Time Frame: 30 days after intervention (year of intervention)

Feasibility will be measured through the completion of the validated, 4-item, Feasibility of Intervention Measure (FIM). Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). The score is calculated as the mean. The scale for this measure ranges from 4-20 with higher scores indicating greater perceived feasibility of the intervention.

Secondary Outcomes

  • All-cause 30-day ED visits(30 days following post-Index heart failure Hospitalization.)
  • Days at home among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims(During a 12-month period (year of intervention))
  • Acceptability of I-TRANSFER-HF - Qualitative Interviews(30 days after intervention (year of intervention))
  • Acceptability of Intervention Measure for the I-TRANSFER-HF Study - Survey(30 days after intervention (year of intervention))
  • Fidelity of I-TRANSFER-HF (Participant-Completed)(30 days after intervention (year of intervention))
  • Fidelity of I-TRANSFER-HF (Observational Ratings)(30 days after intervention (year of intervention))
  • Adaptation of I-TRANSFER-HF(30 days after intervention (year of intervention))

Study Sites (2)

Loading locations...

Similar Trials